3 DCRT联合TP方案同步放化疗治疗Ⅲ期非小细胞肺癌的临床疗效

摘要

Objective:To analyzed the clinical efficacy of 3DCRT combined with docetaxel/paclitaxel plus cispla-tin(TP)concurrent chemoradiotherapy for stage non-small cell lung cancer.Methods:In the study,a total of 86 ca-ses with Ⅲ stage NSCLC in our in-patient department from January 2010 to October 2013 were analysed.These pa-tients were divided into experimental group and control group,43 cases in each.The experimental group received 3DCRT combined with docetaxel/paclitaxel plus cisplatin(TP)concurrent chemoradiotherapy,while the control group was only acceppted by 3DCRT.Following with chemotherapy.After that,all the data,including responses,survival rate and toxicity were collected and analysed.Results:After analysis of these data,the respones rate of the experimental group was significantly higher than that of control group(81.40%vs 58.14%,P=0.019).The 2 year-survival tate of the experimental group was significantly higher than that of control group(51.16%vs 27.91%,P=0.027).Bone marrow toxicity reaction is significantly higher than the control group,but not present irreversible major complications after symptomatic treatment.Conclusion:The shot-and long-term clinical curative effect of chemoradiation for Ⅲstage NSCLC patients is remarkable,toxic and adverse reaction does not affect the treatment plan.%目的：分析3 DCRT联合TP方案同步放化疗治疗Ⅲ期非小细胞肺癌的临床疗效分析。方法：选取2010年1月－2013年10月期间在我院初治的86例Ⅲ期NSCLC患者分为试验组与对照组各43例。试验组采用TP方案同步放化疗，对照组单纯放疗；两组患者放疗结束后继续序贯化疗；评价两组患者的近、远期疗效和不良反应。结果：整理分析后发现，试验组的有效率为81．40％，显著高于对照组58．14％，差异有统计学意义（P＝0．019）；试验组2年生存率51．16％，高于对照组27．91％，差异有统计学意义（P＝0．027）；不良反应骨髓毒性反应显著高于对照组，但经对症治疗后未出现不可逆重大并发症。结论：3 DCRT联合TP方案同步放化疗治疗Ⅲ期非小细胞肺癌的近、远期临床疗效是显著的，毒副反应不影响治疗计划。